ArticleScience advances2024
CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Association of Alzheimer's disease progression with YKL40 levels in peripheral blood and cerebrospinal fluid: a systematic review and meta-analysis.Frontiers in neurologyPooled it
- Inhibition of p38α MAPK increases short-term astrocyte reactivity: the exploratory VIP trial in early Alzheimer's disease.Journal of neuroinflammation · 2025Trial
- The association between Naples prognostic score and cognitive function in older adults: A cross-sectional study of NHANES 2011 to 2014.Medicine · 2026Article
- Differential DNA methylation in blood as potential mediator of the association between ambient PMMolecular psychiatry · 2026Article
- REG4 serves as a prognostic biomarker for pancreatic cancer with long-standing diabetes mellitus by modulating chemoresistance.Translational oncology · 2026Article
- Sex-aware causal inference assessment of the immune system in complex neurodegenerative diseases.Brain : a journal of neurology · 2026Article
- Illuminating proinflammatory myeloid cells with PET tracers targeting GPR84.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- [Progress on prognostic assessment methods for mild cognitive impairment].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Review
- Neuronal APOE4-induced early hippocampal network hyperexcitability in Alzheimer's disease pathogenesis.Nature aging · 2026Article
- Cerebrospinal fluid proteomic signatures revealResearch square · 2026Article
- Circulating inflammatory proteins predict dementia risk, and are linked to structural brain changes and modifiable risk factors.Alzheimer's research & therapy · 2026Article
- Tracing neuroinflammation in neurodegeneration: insights from a scoping review on biofluid biomarkers.Brain communications · 2026Review
- Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes.Frontiers in clinical diabetes and healthcare · 2026Review
- Proteins Associated with Cognition in Amyloid-beta Positive Elders Based on Cerebrospinal Fluid Proteomics.Molecular neurobiology · 2025Article
- The influence of depression onset timing after gastrointestinal diseases on dementia risk.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Potential associated factors of postoperative neurocognitive dysfunction in elderly patients: precursor of BDNF and mature BDNF in serum.Aging clinical and experimental research · 2025Article
- Effect of neuroinflammation on the progression of Alzheimer's disease and its significant ramifications for novel anti-inflammatory treatments.IBRO neuroscience reports · 2025Review
- A compilation of reported alterations in the cerebrospinal fluid proteome in Alzheimer's disease.Brain communications · 2025Review
- APOE ε4-associated downregulation of the IL-7/IL-7R pathway in effector memory T cells: Implications for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?Journal of neuroinflammation · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 4 institutions in 1 country.
Francis ShueDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0003-1659-1952
Launia J WhiteDivision of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0003-0251-9431
Rachel HendrixDepartment of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0002-8263-9988
Jason UlrichDepartment of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0002-4743-926X
Rachel L HensonDepartment of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0002-0664-0629
William KnightDepartment of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.
Yuka A MartensDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0002-5194-4269
Ni WangDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Bhaskar RoyDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Skylar C StarlingDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Yingxue RenDivision of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, USA.
Chengjie XiongDivision of Biostatistics, Washington University School of Medicine, St. Louis, MO 93110, USA.
Yan W AsmannDivision of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0002-8896-2647
Jeremy A SyrjanenDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester MN 55905, USA.ORCID 0000-0001-5990-8206
Maria VassilakiDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester MN 55905, USA.ORCID 0000-0001-8328-136X
Michelle M MielkeDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester MN 55905, USA.ORCID 0000-0001-7177-1185
Jigyasha TimsinaDepartment of Psychiatry, Washington University School of Medicine, St. Louis, MO 93110, USA.ORCID 0000-0003-4794-9187
Yun Ju SungDepartment of Psychiatry, Washington University School of Medicine, St. Louis, MO 93110, USA.ORCID 0000-0002-8021-4070
Carlos CruchagaDepartment of Psychiatry, Washington University School of Medicine, St. Louis, MO 93110, USA.ORCID 0000-0002-0276-2899
David M HoltzmanDepartment of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0002-3400-0856
Guojun BuDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0003-3491-1016
Ronald C PetersenDepartments of Neurology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-8178-6601
Michael G HeckmanDivision of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, USA.
Takahisa KanekiyoDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0001-6751-9374
Mayo Clinic in Florida · USHope Center for Neurological Disorders · USWashington University in St. Louis · USMayo Clinic · US
Funding
SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6MProject 4 (Genetic modifiers for APOE-associated Alzheimer's disease pathogenesis)U19AG069701 · NIA · MAYO CLINIC JACKSONVILLE · PI DAVID M. HOLTZMAN · 2021 to 2026
$42.0MResearch Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5MUSING QUANTITATIVE TRAITS TO IDENTIFY NOVEL GENES FOR ALZHEIMERS DISEASE AND OTHER COMPLEX TRAITSRF1AG053303 · NIA · WASHINGTON UNIVERSITY · PI CLIMER, SHARLEE, CRUCHAGA, CARLOS · 2016 to 2020
$4.0MImpact of ApoE2 on aging-related conditionsRF1AG057181 · NIA · MAYO CLINIC JACKSONVILLE · PI KANEKIYO, TAKAHISA · 2018 to 2018
$3.7MGENETIC MODIFIERS OF CEREBROSPINAL FLUID TREM2 IN ALZHEIMER'S DISEASERF1AG058501 · NIA · WASHINGTON UNIVERSITY · PI CRUCHAGA, CARLOS, PICCIO, LAURA · 2018 to 2018
$3.5MThe Familial Alzheimer Sequencing (FASe) ProjectU01AG058922 · NIA · WASHINGTON UNIVERSITY · PI CRUCHAGA, CARLOS, GOATE, ALISON M · 2018 to 2022
$3.5MSex-specific Molecular Profiling to Understand Pathology and Identify Causal Genes and Drug Targets for Alzheimer's DiseaseRF1AG074007 · NIA · WASHINGTON UNIVERSITY · PI SUNG, YUNJU · 2021 to 2021
$2.7MIDENTIFYING RARE VARIANTS THAT INCREASE RISK FOR ALZHEIMER'S DISEASER01AG044546 · NIA · WASHINGTON UNIVERSITY · PI CRUCHAGA, CARLOS · 2013 to 2017
$2.7MTherapeutic Strategy to Treat Alzheimer's Disease by VGF Delivery into BrainR01AG083981 · NIA · NORTH DAKOTA STATE UNIVERSITY · PI Takahisa Kanekiyo, Jagdish Singh · 2023 to 2026
$2.4MNeuronal ABCA7 loss of function and Alzheimer’s diseaseRF1AG081203 · NIA · MAYO CLINIC JACKSONVILLE · PI KANEKIYO, TAKAHISA · 2023 to 2023
$2.1MBrain Neurotropic Growth Factor Delivery to Prevent and Treat Alzheimer’s DiseaseR01AG051574 · NIA · NORTH DAKOTA STATE UNIVERSITY · PI KANEKIYO, TAKAHISA, SINGH, JAGDISH · 2016 to 2020
$2.0MNIA NIH HHS P30 AG062677NIA NIH HHS R01 AG044546NIA NIH HHS R01 AG051574NIA NIH HHS R01 AG071226NIA NIH HHS RF1 AG053303NIA NIH HHS RF1 AG057181NIA NIH HHS RF1 AG058501NIA NIH HHS RF1 AG068034NIA NIH HHS RF1 AG071226NIA NIH HHS RF1 AG074007NIA NIH HHS RF1 AG081203NIA NIH HHS U01 AG006786NIA NIH HHS U01 AG058922NIA NIH HHS U19 AG069701
Abstract
The immune system substantially influences age-related cognitive decline and Alzheimer's disease (AD) progression, affected by genetic and environmental factors. In a Mayo Clinic Study of Aging cohort, we examined how risk factors like APOE genotype, age, and sex affect inflammatory molecules and AD biomarkers in cerebrospinal fluid (CSF). Among cognitively unimpaired individuals over 65 (
Indexed as
Alzheimer DiseaseCognitive DysfunctionAgedAmyloid beta-PeptidesBiomarkersHumansPeptide Fragmentstau ProteinsAmyloid beta-PeptidesBiomarkersPeptide Fragmentstau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.